Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This review explains why the FDA gave Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD. It summarizes six Phase 2 trials (2004–2017) in which MDMA was given in up to three 8-hour sessions combined with preparatory and follow-up therapy, and pooled analyses showed a large effect on PTSD symptoms and…
This paper reviews research from the last two decades showing ketamine can be a safe, fast-acting, and sustained antidepressant that helps some people with treatment-resistant depression. The authors describe several possible ways ketamine works: blocking NMDA receptors (a brain receptor), boosting new synapse growth and plasticity, reducing inflammation, creating high-entropy…
